title: [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
abstract: TS-1 is an antitumor drug including 5-chloro-2,4 dihydroxypyridine (CDHP), which inhibits dihydriopyrimidine dehydrogenase (DPD) activity selectively in metabolism of 5-FU. However, TS-1 therapy tends to increase adverse events for patients with impaired renal function due to excessively high blood concentration of 5-FU, because CDHP is mainly excreted into the urine. In a 67-year-old male with advanced gastric cancer, renal dysfunction occurred during TS-1 administration as its adverse event. We studied the pharmacokinetics of 5-FU, which were analyzed on the T1/2 value and the AUC (0-infinity) of 5-FU with a single and consecutive TS-1 administration, and estimated an optimal TS-1 administration regimen for this patient. The regimen is 60 mg/body/day given in one divided dose for 28 days consecutively followed by 14 days rest. This regimen enabled a continuation of TS-1 treatment for the patient. In conclusion, individual dose adjustment using pharmacokinetic study of 5-FU might be beneficial to patients with impaired renal function.
authors.affiliation: Dept. of Surgery, Sakai Municipal Hospital.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Junichi
authors.initials: J
authors.lastname: Tanaka
authors.forename: Ryota
authors.initials: R
authors.lastname: Oshiro
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tatsuta
authors.forename: Seizo
authors.initials: S
authors.lastname: Masutani
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakayama
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Takemoto
authors.forename: Motoi
authors.initials: M
authors.lastname: Kondo
authors.forename: Shunji
authors.initials: S
authors.lastname: Kamigaki
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kawasaki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004338:Drug Combinations; D006801:Humans; D007674:Kidney Diseases / Q000150:complications* / Q000378:metabolism; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid